A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

November 4, 2028

Study Completion Date

November 4, 2028

Conditions
Sickle Cell DiseaseVaso-occlusive CrisisVaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
DRUG

Inclacumab

Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Trial Locations (49)

123

Sultan Qaboos University Hospital, Muscat

10461

Jacobi Medical Center, The Bronx

27705

Duke University Medical Center, Durham

27710

DUMC Investigational Drug Services Pharmacy, Durham

30100

International Cancer Institute, Eldoret

36604

Strada Patient Care Center, Pediatric Hematology, Mobile

University of South Alabama Children's and Women's Hospital, Mobile

40600

KEMRI/CRDR Siaya Clinical Research Annex, Kisumu

48109

University of Michigan Hospitals - Michigan Medicine, Ann Arbor

60612

University of Illinois at Chicago (UIC) Clinical Research Center, Chicago

University of Illinois Hospital and Health Sciences System (UI Health), Chicago

72202

Arkansas Children's Hospital, Little Rock

77030

McGovern Medical School at UTHealth, Houston

UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital, Houston

UT Physicians Comprehensive Sickle Cell Center Houston, Houston

82943

Prince Mohammed bin Nasser Hospital, Jizan

92868

UC Irvine Medical Center, Orange

100254

Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital, Lagos

200001

Sociedad de Oncología y hematología del Cesar, Valledupar

460000

University of Nigeria Teaching Hospital, Enugu

540242

University of Calabar Teaching Hospital, Calabar

700223

Aminu Kano Teaching Hospital, Kano

800212

Barau Dikko Teaching Hospital/Kaduna State University, Kaduna

810105

Ahmadu Bello University Teaching Hospital, Zaria

900211

National Hospital Abuja, Abuja

902101

University of Abuja Teaching Hospital, Gwagwalada

06030

UConn-Neag Comprehensive Cancer Center, Farmington

02115

Brigham And Woman's Hospital, Boston

02215

Dana-Farber Cancer Institute IDS Pharmacy, Boston

Dana-Farber Cancer Institute, Boston

41253-190

Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael, Salvador

50070-460

Multihemo Servicos Medicos S/A, Recife

90035-903

Hospital de Clínicas de Porto Alegre, Porto Alegre

14051-140

Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto

15090-000

Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto

20211-030

Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO, Rio de Janeiro

01232-010

Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A, São Paulo

08270-070

Casa de Saude Santa Marcelina, São Paulo

08270-120

CEPEC-Centro de Pesquisa Clinica, São Paulo

080020

Clinica de la Costa Ltda., Barranquilla

00100

Gertrude's Children's Hospital, Nairobi

Kenya Medical Research Institute - Centre for Respiratory Disease Research, Nairobi

00200

Strathmore University CREATES, Nairobi

Unknown

American University of Beirut Medical Center, Hamra

Nini Hospital, Tripoli

NIMR-Mbeya Medical Research Center, Mbeya

01130

Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji, Adana

01250

Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology, Adana

06430

Hacettepe University Ihsan Dogramaci Children Hospital, Ankara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05348915 - A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease | Biotech Hunter | Biotech Hunter